Core Points - PharmaDrug Inc. has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of previously matured debentures [1][2] - The new debentures will mature on October 13, 2026, and are convertible into common shares at a price of $0.05, subject to adjustment [2] - The debentures will be secured by a general security agreement and will not bear interest unless the principal is not paid at maturity, in which case they will accrue interest at 22% per annum [2] Company Overview - PharmaDrug is a specialty pharmaceutical company focused on the research, development, and commercialization of natural medicines, including psychedelics and previously approved drugs [4] - The company owns 51% of Sairiyo Therapeutics, which specializes in researching and reformulating established natural medicines for clinical trials and regulatory approval in the US and Europe [4] - Sairiyo is developing a patented reformulation of cepharanthine, which has shown potential for treating infectious diseases and rare cancers, and is also conducting R&D in the psychedelics space for non-neuropsychiatric conditions [4]
PharmaDrug Announces Debt Restructuring
Newsfile·2025-10-31 12:58